Sun Pharma Industries has received approval from the Central Drugs Standard Control Organization (CDSCO) Panel to manufacture and market Elagolix Tablets in strengths of 150 mg and 200 mg. This approval allows Sun Pharma to produce and sell these tablets in the market. The company’s decision to manufacture and market these tablets has been met with positive feedback, as it will offer patients access to an important medication. Additionally, Sun Pharma’s commitment to quality and safety standards have been acknowledged, further enhancing the company’s reputation in the pharmaceutical industry.
Source link
Sun Pharma Industries Gets CDSCO Panel Nod To Manufacture Market Elagolix Tablets 150 mg,200 mg
